Open Access Open Access  Restricted Access Subscription Access

Biobusiness in Brief:What Ails Clinical Trials?


Affiliations
1 Institute of Bioinformatics and Applied Biotechnology, Biotech Park, Electronics City, Phase I, Bengaluru 560 100, India
 

Many academic researchers, while working on fundamental problems, hope that in due course their science will benefit humanity. Undoubtedly, they would be delighted if their science was to be the basis for drugs that reached patients. For that to happen, the candidate molecules must pass through clinical trials. Unfortunately, world over, trials have been beset with problems and have been heavily criticized on many fronts. Here we describe some of the points of contention, focusing on issues that have come to light in the West.

Keywords

Biotech Industry, Clinical Trials, Ethics, Pharma Industry.
User
Notifications
Font Size


  • Biobusiness in Brief:What Ails Clinical Trials?

Abstract Views: 509  |  PDF Views: 160

Authors

Gayatri Saberwal
Institute of Bioinformatics and Applied Biotechnology, Biotech Park, Electronics City, Phase I, Bengaluru 560 100, India

Abstract


Many academic researchers, while working on fundamental problems, hope that in due course their science will benefit humanity. Undoubtedly, they would be delighted if their science was to be the basis for drugs that reached patients. For that to happen, the candidate molecules must pass through clinical trials. Unfortunately, world over, trials have been beset with problems and have been heavily criticized on many fronts. Here we describe some of the points of contention, focusing on issues that have come to light in the West.

Keywords


Biotech Industry, Clinical Trials, Ethics, Pharma Industry.

References





DOI: https://doi.org/10.18520/cs%2Fv115%2Fi9%2F1648-1652